Virbac stock eases as investors watch 2026 guidance

Published on 09/15/2026 at 10:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac stock lacks a fresh price snapshot in the available hits. MarketBeat shows a Reduce consensus and a USD 145.50 target for Virtus Investment Partners.

Modernes Pharmawerk für Tiergesundheit in sonniger südfranzösischer Landschaft — Fotorealistische Aufnahme zeigt Veterinärpharma-Anlage von Virbac S.A., passend zu ISIN FR0000031577, moderner Standort Südfrankreich, Illustration mit AI erstellt.

Virbac stock (ISIN FR0000031577) is in view as investors weigh the latest analyst tone against the company's most recent reported figures and the next reporting calendar. The available hits point to a focus on earnings quality, margin trends and the timing of the next update.

Analyst tone stays cautious

According to MarketBeat on September 15, 2026, the cited consensus view is Reduce with an average price target of USD 145.50 for Virtus Investment Partners, while the stock last traded at USD 143.76. The same report says one analyst rates the shares Buy, two Hold and two Sell.

The same MarketBeat item also puts the 200-day moving average at USD 147.72 and the intraday high at USD 148.78, which frames the move as a short break above a watched technical level rather than a broad trend shift. The share price was USD 143.76 at the latest trade in that snapshot, and reported volume reached 97,947 shares.

What the numbers show

For Virbac, the most useful read-through is the combination of price discipline and reporting cadence. A visible current catalyst was not substantiated in the available hits, so the numbers that matter most are the latest market values, the analyst stance and the next company update.

Consensus data in the available material also show a clear spread between the 200-day moving average of USD 147.72 and the 52-week high context embedded in the same trading view, while the latest reported share price of USD 143.76 still sits below that average. The report further notes a market capitalization of USD 952.12 million, a P/E ratio of 8.51 and a beta of 1.35.

Virbac stock at a glance

On the latest quoted session in the available material, the reference price was USD 143.76, with a daily move of minus 2.5 percent and volume of 97,947 shares. For Virbac stock, the next step is the company update and the fresh operating figures that will clarify whether valuation and earnings expectations are moving in the same direction.